Drugs / PP-F11N LUTETIUM
PP-F11N LUTETIUM
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03647657 | Dec 2018 → Dec 2021 | medullary thyroid gland carcinoma | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02088645 | Apr 2015 → Apr 2027 expected | lung neuroendocrine neoplasm, medullary thyroid gland carcinoma, thymic neuroendocrine tumor | University Hospital, Basel, Switzerland | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PP-F11N LUTETIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4651038 ↗ |
| Known as | 177Lu-PP-F11N | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03647657 ↗ |
| Known as | Lutetium lu 177 pp-f11n | ChEMBL registry synonym — accepted as the source's own label CHEMBL4651038 ↗ |
| Known as | PP-F11N LUTETIUM LU-177 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4651038 ↗ |
| Known as | PP-F11N(177LU) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4651038 ↗ |
| Action | Activate | “by the cholecystokinin-2 receptor agonist [177Lu]Lu-PP-F11N” PMID 38581480 ↗ Apr 2024 |
| Modality | Protein / enzyme biologic | — CHEMBL4651038 ↗ |
| Route | Intravenous | “intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N” NCT02088645 ↗ |